🔎 Trials Near Me

መነሻ › አኩት ማይሎይድ ሊውኬሚያ › ማሳቹሴትስ › Boston

በBoston፣ MA ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ክሊኒካዊ ጥናቶች

ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ 44 ጥናቶች በBoston እና በአካባቢው ባሉ ቦታዎች (በወደ 30 ማይል ውስጥ) ተሳታፊዎችን እየፈለጉ ነው። ማን መሳተፍ እንደሚችል እና የጥናት ቡድኑን እንዴት መገናኘት እንደሚቻል ለማየት ጥናቱን ክፈቱ።

Official study text (English)

ለጥናት ተሳታፊዎችን እየፈለጉ ነው? በዚህ ገጽ ላይ በ$99 ለ30 ቀናት ያስቀምጡት →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Tufts Medical Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT05564390

Ivosidenib as Post-HSCT Maintenance for AML

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Massachusetts General Hospital, Boston
  • Dana Farber Cancer Institute, Boston
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ5 ኦክቶ 2026 · NCT06707493

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ1 ኦክቶ 2026 · NCT06484062

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Tufts Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ28 ሴፕቴ 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Dana Farber Cancer Institute, Boston
  • Beth Israel Deaconess Medical Center, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06852222

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Tufts Medical Center, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Tufts Medical Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ ከ18 እስከ 59 · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Tufts Medical Center, Boston
  • Beth Israel Deaconess Medical Center, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ22 ሴፕቴ 2026 · NCT06317649

A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and Revumenib

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Dana-Farber Cancer Center, Boston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ሴፕቴ 2026 · NCT06284486

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Massachusetts General Hospital Cancer Center, Boston
  • Dana-Farber Cancer Institute, Boston
6 Months – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ17 ሴፕቴ 2026 · NCT04293562

(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ15 ሴፕቴ 2026 · NCT04996875

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ14 ሴፕቴ 2026 · NCT03471260

Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Massachusetts General Hospital, Boston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ3 ሴፕቴ 2026 · NCT04588922

CIML NK Cells With Venetoclax for AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ28 ኦገስ 2026 · NCT06152809

Assessing PI3K Gamma Inhibition With Azacitidine, Venetoclax and Eganelisib in Patients With Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Brigham and Women's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
እድሜ ከ18 እስከ 90 · ሁሉም ጾታዎች · የተሻሻለው በ26 ኦገስ 2026 · NCT07439211

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT06533761

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Dana-Farber Cancer Institute, Boston
እስከ እድሜ 22 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT04726241

A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations Disease

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana-Farber Cancer Institute, Boston
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ25 ኦገስ 2026 · NCT05886049

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

ተሳታዮችን በመፈለግ ላይደረጃ 3
  • Dana-Farber Cancer Institute, Boston
29 Days – 21 Years · ሁሉም ጾታዎች · የተሻሻለው በ24 ኦገስ 2026 · NCT05183035

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Beth Israel Deaconess Medical Center, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦገስ 2026 · NCT06001788

A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

ተሳታዮችን በመፈለግ ላይደረጃ 1ጤናማ ተሳታዮች ይቀበላሉ
  • Brigham and Women's Hospital, Boston
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ28 ጁላይ 2026 · NCT07020533

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Tufts Medical Center, Boston
  • Beth Israel Deaconess, Boston
  • Dana Farber Cancer Institute, Boston
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ6 ጁላይ 2026 · NCT01351545

A Phase 1 Trial of CIML NK Cell Infusion for Myeloid Disease Relapse After Hematopoietic Cell Transplantation

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Boston Children's Hospital, Boston
  • Dana Farber Cancer Institute, Boston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁን 2026 · NCT04024761

Preemptive CIML NK Cell Therapy After Hematopoietic Stem Cell Transplantation

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana-Farber Cancer Institute, Boston
  • Brigham and Women's Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁን 2026 · NCT06138587

SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ17 ጁን 2026 · NCT03113643

Study of MGUS, Smoldering Myeloma, Early MDS and CLL to Assess Molecular Events of Progression and Clinical Outcome

ተሳታዮችን በመፈለግ ላይየመመልከት ጥናት
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ7 ሜይ 2026 · NCT02269592

Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana Farber Cancer Institute, Boston
እድሜ 13 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT04771572

Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Beth Israel Deaconess Medical Center, Boston
ለሁሉም እድሜ · ሁሉም ጾታዎች · የተሻሻለው በ5 ሜይ 2026 · NCT07374029

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

ተሳታዮችን በመፈለግ ላይደረጃ 2/3
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ30 ኤፕሪ 2026 · NCT04256317

BCL2i CLAG-M in R/R Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Dana-Farber Cancer Institute, Boston
እድሜ ከ18 እስከ 80 · ሁሉም ጾታዎች · የተሻሻለው በ1 ኤፕሪ 2026 · NCT06660368

Revumenib in Combination With 7+3 + Midostaurin in AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana-Farber Cancer Institute, Boston
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ25 ማርች 2026 · NCT06313437

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Massachusetts General Hospital, Boston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ24 ማርች 2026 · NCT04988555

Ziftomenib Maintenance Post Allo-HCT

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ19 ማርች 2026 · NCT06440135

A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation

ተሳታዮችን በመፈለግ ላይደረጃ 2
  • Dana-Farber Cancer Institute, Boston
እድሜ ከ18 እስከ 66 · ሁሉም ጾታዎች · የተሻሻለው በ17 ማርች 2026 · NCT06859424

A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana Farber Cancer Institute, Boston
እድሜ 12 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ16 ማርች 2026 · NCT06994676

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ13 ማርች 2026 · NCT05735184

CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant

ተሳታዮችን በመፈለግ ላይደረጃ 2ጤናማ ተሳታዮች ይቀበላሉ
  • DFCI/BWH Brigham and Women's Hospital, Boston
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ10 ማርች 2026 · NCT06059391

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • DFCI, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ9 ፌብሩ 2026 · NCT06950034

A Multi-Site Break Through Cancer Trial: Targeting Measurable Residual Disease in Patients With Acute Myeloid Leukemia: A Phase 1/2 Study of Tagraxofusp, Azacitidine, and Venetoclax

ተሳታዮችን በመፈለግ ላይደረጃ 1/2
  • Brigham and Women's Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ5 ፌብሩ 2026 · NCT07148180

Novel Digital Application for Patients With Acute Leukemia

ተሳታዮችን በመፈለግ ላይ
  • Massachusetts General Hospital (MGH), Boston
እድሜ ከ18 እስከ 120 · ሁሉም ጾታዎች · የተሻሻለው በ10 ኖቬም 2025 · NCT06472128

IS-free Treg HaploHCT

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana Farber Cancer Institute, Boston
እድሜ ከ18 እስከ 75 · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦክቶ 2025 · NCT04678401

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

ተሳታዮችን በመፈለግ ላይጤናማ ተሳታዮች ይቀበላሉ
  • Massachusetts General Hospital, Boston
  • Dana-Farber Cancer Institute, Boston
እድሜ ከ18 እስከ 120 · ሁሉም ጾታዎች · የተሻሻለው በ25 ጁላይ 2025 · NCT05237258

BXCL701 Phase 1 R/R Acute Myeloid Leukemia or Myelodysplastic Syndrome

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Dana Farber Cancer Institute, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ18 ጁላይ 2025 · NCT05703542

Study of REM-422 in Patients With AML or Higher Risk MDS

ተሳታዮችን በመፈለግ ላይደረጃ 1
  • Massachusetts General Hospital, Boston
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ23 ኤፕሪ 2025 · NCT06297941

በሌሎች ከተሞች ለአኩት ማይሎይድ ሊውኬሚያ የሚደረጉ ጥናቶች

በBoston ውስጥ ያሉ ሌሎች ጥናቶች

ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ6 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።